High-performance, reproducible conjugation with minimal antibody and protein aggregation. No outsourcing required—maintain full control by performing conjugation in your own lab.

CellMosaic^® expands its proven bioconjugation toolkit with a new line of antibody and protein labeling kits powered by AqT^® linker technology and PerKit^® systems—designed to simplify conjugation of challenging hydrophobic detection or tagging reagents while preserving protein and Ab functionality.

Why Choose AqueaTether^® (AqT^®) Enabled Labeling Kits?

• Improves the solubility of hydrophobic labels in aqueous buffers, eliminating the need for organic solvents in your system.
• Reduces protein and Ab aggregation for stable conjugates and reproducible assay performance.
• Preserves protein and Ab activity and binding performance.
• Delivers high labeling efficiency with consistent results.
• Enables simple, in-house workflows—no CRO required.

Available Labeling Options

AqT^® Biotin Labeling Kits

Generate highly biotinylated conjugates with excellent stability and minimal aggregation.

CM86143 – AqT^® Biotin Protein Labeling Kit: labels 6.67–20 nmol of protein.

CM86144 – AqT^® Biotin Antibody Labeling Kit: labels 0.1 mg, 0.1–1 mg, or 1–3 mg of antibody.

AqT^® Digoxigenin Labeling Kits

Reliable DIG labeling with low aggregation and high conjugate quality.

CM86442 – AqT^® Digoxigenin Protein Labeling Kit: labels  6.67–20 nmol of protein.

CM86440 – AqT^® Digoxigenin Antibody Labeling Kit: labels 0.1 mg, 0.1–1 mg, or 1–3 mg of antibody.

AqT^® Fluor 750 Labeling Kits

These kits incorporate a near-infrared fluorophore (Ex/Em: 750/780 nm) and an AqT^® spacer to enhance conjugate brightness, stability, and performance while preserving protein & Ab functionality.

CM86256 – AqT^® Fluor 750 Protein Labeling Kit: labels 6.67–20 nmol of protein.

CM86248 – AqT^® Fluor 750 Antibody Labeling Kit: labels 0.1 mg, 0.1–1 mg, or 1–3 mg of antibody.

AqT^® ADC Dual (Drug/Biotin and Drug/Fluor 750) Labeling Kits

Designed for antibody-drug conjugate (ADC) detection workflows, these kits are fully compatible with CellMosaic ADC kit workflows.

CM86145 – AqT^® Biotin ADC Labeling Kit: labels 0.1 mg or 1–3 mg of antibody.

CM86264 – AqT^® Fluor 750 ADC Labeling Kit: labels 0.1 mg or 1–3 mg of antibody.

Built on Proven Technologies

AqT^® Linker Technology

AqT^® technology enables conjugation of hydrophobic molecules while maintaining solubility, stability, and native protein & antibody functions.

PerKit^®

These are complete, ready-to-use kits with optimized reagents and protocols—making advanced bioconjugation accessible in any lab.

About CellMosaic, Inc.

Founded in 2008, CellMosaic^® has been a pioneer in bioconjugation, delivering high-quality solutions powered by proprietary AqueaTether^® (AqT^®) technologies and advanced bioconjugation processes to advance next-generation bioconjugates and targeted therapeutics.

We are thrilled to announce that our patent application has been granted by the Brazilian Patent Office! The granted patent, BR112014000324-6, is titled “Sugar-alcohol-based crosslinking reagents, macromolecules, therapeutic bioconjugates, and synthetic methods thereof.”

It took an awfully long time to get this patent approved, but we are delighted that it has finally been allowed. This achievement marks another important milestone in our mission to improve how medicines reach their targets. It also adds to our growing IP portfolio of 13 patents and demonstrates our continued leadership in bioconjugation technology.

A special thank you to our research team and our IP counsel partners for their dedication and efforts in making this success possible.

About CellMosaic, Inc.

CellMosaic® Inc. is a Massachusetts-based biotech company dedicated to creating high-quality, innovative, and advanced bioconjugates. Bioconjugates are used broadly as research tools, diagnostic reagents, and a novel modality for drugs. Due to the complexities of the bioconjugation process and requirement of techniques and knowledge across multidisciplinary fields, not many companies are competent to offer high-quality bioconjugation services and to provide high-quality bioconjugates. CellMosaic was established in 2008 to fill this gap and has since spent a lot of research effort on developing innovative linkers, crosslinking technologies, and advanced bioconjugation processes. CellMosaic’s current business is organized into four units: 1) Reagent/kit business commercializing bioconjugate reagents and personalized bioconjugation kits (PerKit®) based on CellMosaic’s advanced bioconjugation processes − many of these PerKits™ are for preparation of advanced bioconjugates by the customer, such as antibody drug conjugates (ADCs), antibody oligo conjugates (AOCs), and single labeled bioconjugates; 2) Custom conjugation services for research bioconjugates; 3) Contract bioconjugate manufacturing focusing on process development, scale-up, and GLP/GMP manufacturing, and 4) AqT® ADC development focusing on licensing and manufacturing next-generation ADCs using super-hydrophilic and high loading AqT® linkers. These four business units complement each other and form an integrated bioconjugation workflow from ideation to commercialization.

About AqueaTether™ (AqT™) Therapeutics

AqT™ Therapeutics, a division of CellMosaic established in 2016, focuses on the discovery and development of novel hybrid drug entities that beyond the conventional drug classes by leveraging AqT™ conjugation and delivery platform technologies. AqT™ drug delivery technologies are engineered to efficiently load and conjugate highly hydrophobic small molecule drugs, such as antibody-drug conjugates (ADCs), or to modify unstable large biologics like antibodies—creating safer, more effective cancer therapies. We collaborate closely with our partners to advance their programs. For more information about AqT™-based bioconjugate drugs, please visit: www.aqttherapeutics.com.

We applaud the collaborative work of researchers from the University of New Mexico (UNM), Duke University, RTI International, and CellMosaic Inc. for the publication of their recent paper in NPJ Vaccines, titled:

"Two doses of QB virus-like particle vaccines elicit protective antibodies against heroin and fentanyl”

Published: March 28, 2025 | DOI: 10.1038/s41541-025-01105-0

Authors: Isabella G. Romano, Susan B. Core, Andzoa N. Jamus, Bryce Chacherain, Kathryn M. Frietze (UNM); Brandi Johnson-Weaver, Herman Staats, William C. Wetsel (Duke University); Marcus Brackeen, Bruce Blough (RTI International); and Yumei Huang, Subhakar Dey (CellMosaic Inc.)

Addressing the Opioid Crisis

OUD is characterized by the misuse of prescription drugs and opioid derivatives. Over the last several decades opioids such as heroin and fentanyl have contributed greatly to the rising overdose rates. In 2022 there were approximately 107,000 drug overdose deaths of those over 70% could be attributed to opioids, a total of approximately 82,000 overdose deaths, according to data from the Centers for Disease Control and Prevention. While treatments such as methadone, buprenorphine, and naloxone (Narcan) are currently available, they present challenges including the need for daily dosing, limited accessibility, and – in the case of Narcan- dependence on others during overdose emergencies.

Vaccines – A Proactive Solution

Vaccines offer a proactive approach to treating OUD and preventing overdoses. These vaccines work by prompting the immune system to generate antibodies that bind to opioid molecules, preventing them from crossing the blood-brain barrier. As a result, the drugs are unable to produce their addictive and harmful effects.

However, opioids on their own do not trigger a strong immune response. To overcome this, researchers conjugate opioid derivatives to immunogenic carriers such as keyhole limpet hemocyanin (KLH) or tetanus toxoid (TT). Earlier vaccine candidates using these carriers showed promise but required three or more doses to be effective.

The development of a two-dose vaccine that produces high-titer, long-lasting, and protective antibody responses could be a game-changer—especially for underserved populations with limited access to medical care.

The QB Virus-Like-Particle (VLP) Design

In this newly published study, researchers detail their work using a Qβ virus-like particles (VLPs)—a highly immunogenic structure derived from RNA bacteriophage Qβ. These VLPs offer several advantages:

• High-density repetitive structure for strong immune activation
• Thermostability and scalability
• Low production cost
• Favorable safety profile in humans
• Compatibility with Good Manufacturing Practice (GMP) standards

Using this platform, the team created vaccine candidates targeting heroin, fentanyl, and a combination of both. This builds on prior work from the same group that focused on an oxycodone vaccine candidate.

CellMosaic’s Role in the Collaboration

Since 2019, we have been working with Professor Frietze’s lab to design and synthesize opioid derivatives suitable for conjugation to Qβ VLPs. The resulting Qβ vaccines, tested in animal models after one or two immunizations demonstrated the ability to produce durable, high-avidity, high-titer antibody responses. Importantly, these vaccines showed protective capabilities against heroin and fentanyl challenge after two immunizations.  

Looking Ahead

This research represents a promising advancement in the fight against opioid addiction. While there are no FDA-approved vaccines yet for substances like heroin, fentanyl, nicotine, or cocaine, studies like this bring us closer to a future without drug overdose deaths.

To explore more about this groundbreaking study and the collaborative effort behind it, read the full publication here, and stay tuned for future developments.

About Frietze’s Lab at University of New Mexico Health Sciences Center

The Frietze lab studies the antibody response to infectious and chronic disease with a goal of translating that knowledge into new vaccines. For more information, please visit the lab’s website.

About CellMosaic® Inc.

CellMosaic is a Massachusetts-based biotech company specializing in the research and drug bioconjugate market. Bioconjugates are widely used as research tools, diagnostic reagents, and novel drug modalities, such as antibody-drug conjugates (ADCs), antibody-oligo conjugates (AOCs). Since its founding in 2008, CellMosaic® has invested significant research efforts in developing core technologies to address two major challenges in the field: advanced bioconjugation processes for producing high-quality bioconjugates and AqT® technologies for efficiently loading large amounts of hydrophobic small molecules onto biomolecules. Operating from its U.S. facility, CellMosaic® currently offers bioconjugation-related reagents and kits, customer bioconjugation services, contract bioconjugate development and manufacturing, and strategic partnerships for developing proprietary innovative AqT® ADC using its novel AqT® linker-modified drugs.

Small Molecule Dye Conjugates: NIR Dye-Polysucrose-400 Conjugates.

Our new near-infrared (NIR) dye-polysucrose-400 conjugates are designed with stable linkages for enhanced performance in permeability studies, cell tracking, drug delivery research, and tissue engineering.

• CM62106 – Cyanine 5.5 Polysucrose-400 (Excitation: 675 nm / Emission: 694 nm)
• CM62105 – Cyanine 7 Polysucrose-400 (Excitation: 750 nm / Emission: 773 nm)

Key Features & Benefits:

• Ready-to-use lyophilized powder – Simply reconstitute with water or aqueous buffers.
• Highly Water-soluble – Easily dissolves in aqueous solutions for seamless integration into various experimental workflows.
• Stable dye conjugation – Ensures minimal dye dissociation.
• High purity – No detectable free dye, verified by SEC HPLC (≥99% purity).
• Optimized molecular weight – Polysucrose 400 has a molecular weight range of 300,000–550,000 g/mol.

Protein Dye Conjugates - R-Phycoerythrin (PE)-Streptavidin Conjugates

Introducing our fluorescent biotin detection reagents, featuring varying degrees of labeling to meet diverse assay requirements:

• CM54201 R-Phycoerythrin (PE)-Streptavidin (1:1) Conjugate
• CM54202 R-Phycoerythrin (PE)-Streptavidin (1:2) Conjugate
• CM54203 R-Phycoerythrin (PE)-Streptavidin HL Conjugate

Why Choose R-Phycoerythrin (PE)?

R-PE is a bright red-orange (Excitation: 565 nm / Emission: 576 nm), fluorescent dye that when conjugated, often provides 5 to 10 times greater sensitivity when compared to fluorescein labeled conjugates. 

What sets our R-PE-Streptavidin conjugates apart?

• Retention of Biotin Binding Activity – Featuring a 29-atom-long, flexible PEG/Ethylene linker, these conjugates preserve streptavidin’s biotin-binding efficiency.
• Versatile Applications – Ideal for fluorescence-based assays, including
• Flow Cytometry
•  ELISAs
•  Microarrays

Explore the latest in fluorescent detection and elevate your research with CellMosaic®.

We’re thrilled to Announce our newest PerKit® additions:

• CM11435 Antibody or Protein Exatecan Conjugation Kit
• CM11436 Antibody or Protein Exatecan Conjugation Kit with VC-PAB Linker
• CM11438 Antibody or Protein SN38 Conjugation Kit with VC-PAB-Linker
• CM11439 Antibody or Protein PBD Dimer Conjugation Kit

Why It Matters:

CellMosaic’s PerKit® revolutionize research by enabling in-house antibody- and protein-drug conjugation, reducing the time needed to develop complex conjugation processes and reliance on expensive CRO services. With all necessary reagents and protocols included, researchers can easily synthesize drug conjugates using their own antibodies/proteins and standard lab equipment.

Key Benefits:

• Simple and efficient labeling of antibody or protein that minimizes toxin exposure
• Fast preparation: 6 hours total, with less than 2 hours of hands-on time.
• Inclusion of all necessary reagents and supplies for preparation and purification.
• Option to choose tailored post-conjugation services at CellMosaic for Analysis and Drug loading determination

Stay ahead in bioconjugation with PerKit® 

-------------------------------------------
About PerKit® Conjugation Kits

Historically, antibody-drug conjugation was conducted primarily by drug developers, sometimes in collaboration with contract research organizations (CROs). However, the high cost of these services often limited research opportunities for academic institutions and small biotech companies.

In December 2017, CellMosaic introduced its first ADC kit product line, empowering researchers to prepare antibody-drug conjugates (ADCs) in-house and significantly reducing reliance on costly CRO services. Each kit includes all necessary reagents and detailed protocols for bioconjugate synthesis, requiring only the customer’s antibody or protein and standard laboratory equipment.

--------------------------------------------
About CellMosaic, Inc.

CellMosaic® Inc. is a Massachusetts-based biotech company dedicated to creating high-quality, innovative, and advanced bioconjugates. Bioconjugates are used broadly as research tools, diagnostic reagents, and a novel modality for drugs. Due to the complexities of the bioconjugation process and requirement of techniques and knowledge across multidisciplinary fields, not many companies are competent to offer high-quality bioconjugation services and to provide high-quality bioconjugates. CellMosaic was established in 2008 to fill this gap and has since spent a lot of research effort on developing innovative linkers, crosslinking technologies, and advanced bioconjugation processes. CellMosaic’s current business is organized into four units: 1) Reagent/kit business commercializing bioconjugate reagents and personalized bioconjugation kits (PerKit®) based on CellMosaic’s advanced bioconjugation processes − many of these PerKits™ are for preparation of advanced bioconjugates by the customer, such as antibody drug conjugates (ADCs), antibody oligo conjugates (AOCs), and single labeled bioconjugates; 2) Custom conjugation services for research bioconjugates; 3) Contract bioconjugate manufacturing focusing on process development, scale-up, and GLP/GMP manufacturing, and 4) AqT® ADC development focusing on licensing and manufacturing next-generation ADCs using super-hydrophilic and high loading AqT® linkers. These four business units complement each other and form an integrated bioconjugation workflow from ideation to commercialization.

Newly Released Products:

• Maleimide Activated BSA ML: 10-20 maleimide groups (2 mg & 6 mg)
• Maleimide Activated BSA LL: 2-8 maleimide groups (2 mg & 6 mg)
• Maleimide Activated KLH ML: 10-30 maleimide groups (2 mg & 6 mg)

Complete Product Line Overview:

Key Features and Benefits:

• Wide Range of Loadings: Products offer maleimide group loadings from 2 to 80 groups per protein, enabling researchers to select the optimal conjugation level for their specific applications.
• Flexible Packaging: Available in 2 mg and 6 mg quantities to meet research and production needs.
• High-Quality Standards: Manufactured under strict quality control for consistent performance and reliability

--------------------------------------------
About CellMosaic, Inc.
CellMosaic is a Massachusetts-based biotech company specializing in the research and drug bioconjugate market. Bioconjugates are widely used as research tools, diagnostic reagents, and novel drug modalities, such as antibody-drug conjugates (ADCs), antibody-oligo conjugates (AOCs). Since its founding in 2008, CellMosaic® has invested significant research efforts in developing core technologies to address two major challenges in the field: advanced bioconjugation processes for producing high-quality bioconjugates and AqT® technologies for efficiently loading large amounts of hydrophobic small molecules onto biomolecules. Operating from its U.S. facility, CellMosaic® currently offers bioconjugation-related reagents and kits, customer bioconjugation services, contract bioconjugate development and manufacturing, and strategic partnerships for developing proprietary innovative AqT® ADC using its novel AqT® linker-modified drugs.

Every 7 minutes, someone in America loses their life to an opioid overdose. While current treatments exist, they have significant limitations - from daily clinic visits for methadone to the need for someone else to administer Narcan during an overdose. Dr. Kathryn Frietze at the University of New Mexico is working on a groundbreaking alternative: a vaccine that could prevent overdoses before they happen. 

On January 21, CellMosaic hosted a special webinar featuring Dr. Kathryn Frietze, Associate Professor at the University of New Mexico's Health Sciences Center, and our CEO, Dr. Yumei Huang. At CellMosaic, we are particularly proud to showcase that our specialized chemistry and bioconjugation expertise - typically used for cancer treatments - is the underlying technology platform behind UNM’s promising research into opioid treatment.

Here's what we learned about this innovative approach to combating the opioid crisis.

You can watch the full video here: 

The Science Behind the Solution

Dr. Frietze's lab is developing medicines that teach the body to recognize and neutralize opioids before they can cause harm. Think of it as creating a biological safety net that catches dangerous drugs before they reach the brain. Key advantages of this approach:

• Protection could last for months with just two doses 

• Proactive, not reactive like current small molecule drug treatments

• Works faster than existing approaches

• Shows promise in preventing respiratory depression during overdose

• Could potentially protect against multiple drugs simultaneously

Why CellMosaic's Technology Matters

When Dr. Frietze needed to attach opioid molecules to her vaccine particles, she faced a crucial challenge: finding someone who could create the precise molecular connections needed. That's where CellMosaic's expertise proved essential:

• We believe we are the only company able to successfully modify both oxycodone and fentanyl for vaccine development

• Delivered solutions quickly using their proprietary processes

• Enabled rapid research progress through reliable manufacturing

Dr. Huang explained CellMosaic's strategic role: "While we're concentrated on cancer treatment, there's significant similarity in developing vaccines and cancer therapies. They share the same core chemistry, manufacturing, and control requirements. Everything is synergetic."

Why This Matters to Biotech Investors

The UNM collaboration showcases CellMosaic's unique market position in the $200B+ drug delivery space. While most biotech investments are binary bets on clinical trials, CellMosaic generates revenue at multiple stages of drug development through:

• Technical Leadership: When UNM needed specialized chemistry to attach opioid molecules to vaccine particles, CellMosaic was the only company they could find that was able to help. CellMosaic's 220+ proprietary processes, developed over 15 years, enabled them to quickly modify both oxycodone and fentanyl - two structurally different drugs that presented unique challenges.

• Diverse Revenue Streams: Research tools, custom manufacturing, and potential licensing opportunities.

• Scalable Platform: The same chemistry expertise that enables cancer drug development applies to vaccines and other therapeutic areas.

• Market Validation: "When we first went out to look for a company that could do [advanced bioconjugation services to create linker molecules&91;, we were having a hard time," noted Dr. Frietze. "CellMosaic immediately said yes and expanded what we were looking at."

Massive Potential Impact 

"Every time I present this work, people come up to tell me about family members, friends, or themselves who have been impacted by the opioid epidemic," Dr. Frietze shared during the webinar. The crisis touches every community: teenagers exposed to contaminated recreational drugs, patients who developed dependency through prescribed medications, and families shattered by overdose losses. With over 5.5 million Americans currently living with opioid use disorder (The Opioid Crisis | NIH HEAL Initiative) and deaths occurring every 7 minutes, the need for better solutions isn't just a market opportunity - it's a moral imperative.

Current treatments leave critical gaps:

• Daily clinic visits create barriers for those without transportation

• Narcan requires someone else to be present during an overdose

• Treatment access remains limited, especially in rural areas

• Growing contamination of other substances with fentanyl puts more lives at risk

A vaccine approach could transform this landscape, potentially providing months of protection with just two doses. "It would be revolutionary," noted Dr. Frietze, particularly for vulnerable populations like recently incarcerated individuals who face the highest risk of fatal overdose.

The potential reach of this technology is significant:

• $5 billion current market for opioid use disorder treatments

• Expected to grow to $10 billion by 2029

• Over 5.5 million Americans currently live with opioid use disorder

• No similar vaccine is currently available on the market

CellMosaic's role becomes particularly crucial as the project moves toward manufacturing milestones. With plans to establish GMP facilities and scale up production capabilities, CellMosaic is positioning itself to support the transition from lab success to clinical development. "We're already supporting the proof-of-concept work," noted Dr. Huang, "and we're preparing our infrastructure to handle the next phases of development."

CellMosaic's Role in the Future

As this research moves forward, CellMosaic is preparing to support larger-scale development. The company is aiming to expand its manufacturing capabilities for clinical trials, build new production facilities, and support CMC (Chemistry, Manufacturing, and Controls) requirements - all while leveraging 15 years of bioconjugation expertise. 

"Everything is synergetic," Dr. Huang explained during the webinar. "The core chemistry, manufacturing, and control requirements we've developed for cancer treatments apply directly to vaccine development."

With the StartEngine campaign closing on January 30th, CellMosaic is positioned at a crucial moment. The company's proven revenue model, validated technology, and expanding applications in critical therapeutic areas like opioid addiction treatment demonstrate its potential impact in the $200B+ drug delivery market. 

While the opioid vaccine development showcases just one application of CellMosaic's technology, it highlights the company's broader mission: providing essential tools and expertise that help bring life-changing treatments to patients.

This application is the first to be granted under a PCT family WO2019/213046 A1 filing titled “Branched Sugar Alcohol-Based Compounds, and Compositions and Methods Thereof.” The patent represents another milestone in our mission to improve how medicines reach their targets. It adds to our growing IP portfolio of 12 patents and demonstrates our continued leadership in bioconjugation technology.

Special thanks to our research team and our partners at the DOD Breast Cancer Research Program, whose support helped make this breakthrough possible.

Breaking Ground: A New Patent for Better Medicine

Innovation in biotech often starts with a document that represents years of research. Here, that document is a USPTO notice of allowance for our newest patent, held proudly by our founder and CEO Dr. Yumei Huang. This patent for branched high-loading AqueaTether® linker technologies emerged from our Department of Defense research collaboration, marking another milestone in our mission to improve drug delivery.

Precision in Every Step

Advanced Purification Technologies

In our analytical lab, our Chief Scientific Officer Dr. Subi Dey operates our Agilent preparative HPLC system with practiced precision. This sophisticated purification process ensures our small molecule drugs meet the exacting standards required for bioconjugation research. Each successful purification brings us closer to our goal of more effective targeted therapies.

Innovative Filtration Processes

At the adjacent station, scientist Katie monitors the µPULSE-TFF system, carefully purifying fluorescent-labeled antibodies. This advanced tangential flow filtration technology represents a crucial step in our bioconjugation process. The purified antibodies will become part of the targeted therapeutics that could help reduce the devastating side effects often associated with treatments like chemotherapy.

From Liquid to Stable Form

Preservation and Stability

Across the room, scientist Annie prepares protein conjugates for lyophilization. Each tray of fluorescent dye-labeled bioconjugates requires precise handling - the freeze-drying process is critical for maintaining product stability. This step transforms liquid solutions into stable, powder forms that researchers can reliably use in their development work.

Quality Control and Shipment

Precision Packaging

In our fulfillment area, Katie meticulously prepares ADC vial shipments. Each of the seven boxes she packs contains more than just products - they carry the potential for advancement in targeted therapeutics. These shipments will support research at some of the 500+ organizations worldwide using our technology to develop better treatments.

Temperature-Controlled Storage

Dr. Huang personally oversees our most sensitive storage protocols. At the -80°C freezer, she retrieves products with the same methodical attention that led her to develop over 220 proprietary bioconjugation methods. Her innovations in chemical technologies have transformed how researchers approach drug delivery challenges, making powerful medicines work better by delivering them precisely where they're needed.

Preparing for Tomorrow's Research

Final Quality Checks

Production specialist John conducts final inspections of our PerKit™ products before careful refrigeration. Each kit represents CellMosaic's commitment to providing researchers with reliable, effective tools for developing targeted therapies. The temperature-controlled storage ensures that products maintain their integrity until they reach research labs around the world.

Looking Forward: The Future of Drug Delivery

Growing Market Presence

Our commitment to advancing drug delivery science has attracted partners from leading research institutions including Stanford and Yale. The global ADC market is projected to reach more than $40 billion by 2029, growing at 22% CAGR. Beyond ADCs, our technology has applications across the broader drug delivery market - from opioid addiction treatment to diabetes - representing a combined opportunity exceeding $200 billion globally.

Continuing Innovation

Every day at CellMosaic builds upon our foundation of scientific excellence. From Dr. Huang's groundbreaking work in bioconjugation to our team's dedication to quality, we're advancing the science of drug delivery across multiple therapeutic areas. While we're proud of our growth and market validation, what truly drives us is knowing that each advance in our technology could mean better outcomes for patients.

As we continue to expand our capabilities and reach, we remain focused on our core mission: making powerful medicines work better by delivering them precisely where they're needed. Every product that leaves our facility carries with it the potential to advance this mission.

CM11434 Antibody Deruxtecan High Loading Conjugation Kit. 

Trastuzumab Deruxtecan, marketed as Enhertu, typically carries an average of 8 Deruxtecan molecules per antibody (Nakada, T. et al., Bioorg. Med. Chem. Lett., 2016, 26, 1542−1545). Previously, we launched the standard Antibody Deruxtecan Kit (CM11431), which targets 4 Deruxtecan molecules per antibody. This new kit allows for higher drug loading, delivering up to 8 Deruxtecan molecules per antibody—similar to Enhertu. It is recommended to first use our standard kit to evaluate your antibody's tolerance for conjugation. Once validated, this high-loading kit can achieve the desired level of conjugation while minimizing aggregation or precipitation issues. 

Key Features: 

• Simple and efficient labeling of IgG with Deruxtecan, minimizing toxin exposure. 
• Includes an enzymatically cleavable GGFG peptide linker. 
• Delivers an average of 8 Deruxtecan molecules per antibody. 
• Fast preparation: only 4 hours total, with less than 1 hour of hands-on time. 
• Includes all necessary reagents and supplies for preparation and purification. 
• Achieves over 95% conjugation, free from unreacted drugs. 
• Post-conjugation services available from CellMosaic® for analysis and DAR determination. 

Learn More on the Product Page! 

CM52427 Streptavidin Oligo Conjugation Kit (Single Label via Click Chemistry) 

Streptavidin-biotin binding systems remain the gold standard for protein and nucleic acid detection and purification. While we previously offered a single-label streptavidin-oligo conjugation kit for amine-modified oligos, this new kit is tailored for DBCO-modified oligos. It supports various oligo configurations and lengths, enabling efficient single-label conjugation with azide-activated streptavidin. 

Key Features: 

• High-quality azide-activated streptavidin for precise single labeling. 
• Single purification step yielding over 90% streptavidin-oligo conjugates, with the majority being single-labeled (assuming high-quality oligos). 
• Quick preparation process, completed within a single day. 
• Stable linkage with an optimized spacer to prevent interference between oligo binding and streptavidin activity. 
• Includes all necessary reagents, from preparation to purification. 
• Tailored post-conjugation services available at CellMosaic®. 

Learn More on the Product Page! 

Both new PerKit® products showcase CellMosaic’s commitment to innovation and customer-driven product development. Whether you're looking to create high-loading ADCs or advanced streptavidin-oligo conjugates, these kits provide reliable, efficient, and high-quality solutions. Visit the product pages to learn more about how these tools can support your research and development needs! 

-------------------------------------------- 

About CellMosaic, Inc. 

CellMosaic® Inc. is a Massachusetts-based biotech company dedicated to creating high-quality, innovative, and advanced bioconjugates. Bioconjugates are used broadly as research tools, diagnostic reagents, and a novel modality for drugs. Due to the complexities of the bioconjugation process and requirement of techniques and knowledge across multidisciplinary fields, not many companies are competent to offer high-quality bioconjugation services and to provide high-quality bioconjugates. CellMosaic was established in 2008 to fill this gap and has since spent a lot of research effort on developing innovative linkers, crosslinking technologies, and advanced bioconjugation processes. CellMosaic’s current business is organized into four units: 1) Reagent/kit business commercializing bioconjugate reagents and personalized bioconjugation kits (PerKit®) based on CellMosaic’s advanced bioconjugation processes − many of these PerKits™ are for preparation of advanced bioconjugates by the customer, such as antibody drug conjugates (ADCs), antibody oligo conjugates (AOCs), and single labeled bioconjugates; 2) Custom conjugation services for research bioconjugates; 3) Contract bioconjugate manufacturing focusing on process development, scale-up, and GLP/GMP manufacturing, and 4) AqT® ADC development focusing on licensing and manufacturing next-generation ADCs using super-hydrophilic and high loading AqT® linkers. These four business units complement each other and form an integrated bioconjugation workflow from ideation to commercialization.